本態性血小板血症の治療

Overview of attention for article published in Nihon Kessen Shiketsu Gakkai shi Japanese journal of thrombosis and hemostasis, August 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,801 followers.

【文献メモ】本態性血小板血症の治療 (日本血栓止血学会誌, 2021, 32(4), 376-382) https://t.co/YRP9meKUqI

14 Mar 2024

Reply Repost Favourite

RT @modRNA_2: 参考 https://t.co/WFbSQPfpcb 1．はじめに "本態性血小板血症（essential thrombocythemia: ET）は骨髄増殖性腫瘍（myeloproliferative neoplasms: MPN）に分類される疾患…

04 Apr 2023

Reply Repost Favourite

参考 https://t.co/WFbSQPfpcb 1．はじめに "本態性血小板血症（essential thrombocythemia: ET）は骨髄増殖性腫瘍（myeloproliferative neoplasms: MPN）に分類される疾患であり，ドライバー変異の存在と血小板を中心とした骨髄系細胞の増加を特徴とする" (続)

04 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.